T-DM1, a combination drug of trastuzumab and a cell-killing drug emtansine, significantly improved progression-free survival in women with advanced HER2-positive breast cancer whose cancer has recurred or progressed despite previous treatments, according to the results of the TH3RESA trial.
A new meta-analysis indicated that people with diabetes are not only at an increased risk of developing breast and colon cancer, but are also at an increased risk of dying from the diseases.
Long-term safety and efficacy results of two phase II trials indicate that dose-dense anthracycline-based chemotherapy with doxorubicin and cyclophosphamide can be safely combined with anti-HER2 therapy in women with early breast cancer.
The FDA today granted pertuzumab (Perjeta) accelerated approval for the treatment of patients with HER2-positive early stage breast cancer prior to surgery who are at high risk for recurrence or metastasis.
A specific pair of proteins more often found in aggressive smoking-related lung adenocarcinomas could serve as a prognostic biomarker for aggressive disease.
The addition of the oral pan-deacetylase inhibitor panobinostat to bortezomib helped to elicit responses in about one-third of heavily pre-treated patients with multiple myeloma who were refractory of bortezomib, according to the phase II results of the PANORAMA 2 study.
Colorectal cancer patients who have early tumor shrinkage after first-line treatment with chemotherapy plus cetuximab may be more likely to have long-term response to therapy, according to an analysis of two large clinical trials.
In the VICTOR trial, patients with PI3KCA-positive colorectal cancer who took aspirin had a lower cancer recurrence compared to those with a wild-type PI3KCA gene.
The combination of two oral targeted agents, dabrafenib (Tafinlar) and trametinib (Mekinist), has been given a priority review by the FDA for the treatment of BRAF V600-positive metastatic melanoma.
Gilead Sciences has submitted an NDA to the FDA for its new drug idelalisib, for the use in patients with indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy.